How to Buy Sab Biotherapeutics Stock
Sab Biotherapeutics Inc
SAB Biotherapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States.
Sab Biotherapeutics stock last closed at $3.51, up 0.29% from the previous day, and has increased 25.81% in one year. It has overperformed other stocks in the Biotechnology industry by 0.48 percentage points. Sab Biotherapeutics stock is currently +89.73% from its 52-week low of $1.85, and -31.84% from its 52-week high of $5.15.
At the moment, there are 90.99M SABS shares outstanding. The market value of SABS is $319.36M. In the past 24 hours, 1.97M SABS shares were traded.
How to Buy Sab Biotherapeutics Stock
Wondering how to invest in Sab Biotherapeutics stock? Here's how.
- Decide where to buy Sab Biotherapeutics stock: You need to decide on a stock brokerage, but don't worry - we've analyzed dozens of stock brokerages and apps to help you figure out where to buy Sab Biotherapeutics stock.
- Create a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Fund your brokerage account: Select your payment method and add your information.
- Research Sab Biotherapeutics stock: The Sab Biotherapeutics ticker symbol is SABS. Is Sab Biotherapeutics stock a good investment? Should you buy shares of SABS? How do SABS's underlying business fundamentals look? Do top analysts think Sab Biotherapeutics is a good buy? Why has SABS's stock price moved recently? (Hint: Our stock market analysis tools can help you understand if SABS is a good stock to buy).
- Make your SABS purchase: Decide if you will purchase SABS shares at the current market price or use a limit order to purchase SABS stock at a specific price.
- Get updates on your SABS investment: Create a watchlist to watch your new investment in Sab Biotherapeutics shares.
Step 1: Decide where to buy Sab Biotherapeutics stock
You need an online brokerage account to access the NASDAQ market and buy SABS shares.
Our recommended brokerage: eToro
Based on our analysis, eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global markets: From Tech to Healthcare, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've selected your brokerage, the next step is to fill out some personal details so you can invest in SABS today.
How to Open a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal details to create a new trading account.
- Send your application by pressing the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you've filled out your info on one of the best stock market apps, you can securely and quickly fund your account:
Check out the video below if you need help depositing money into your investment account.
Step 4: Research Sab Biotherapeutics stock
Once you have identified the best place to buy Sab Biotherapeutics stock, it's crucial to research their stock before you buy, so you actually understand the risk and upside.
Sab Biotherapeutics Metrics
SABS Overview
WallStreetZen was built to help part-time investors perform more accurate fundamental analysis.
You can see all of the due diligence checks on SABS's stock page.
Is SABS stock properly valued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge SABS's fair value.
Using relative valuations measures:
- SABS may be undervalued based on its P/B ratio of 1.49x, relative to Biotechnology industry P/B ratio of 5.28x
You can do additional valuation research on SABS's stock here.
A look at SABS Cashflows and Balance Sheet
Pros:
- SABS has cash burn of 57437506. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the SABS balance sheet.
- SABS has a low debt to equity ratio of 0.11.
- There are more short-term assets than long-term liabilities on the SABS balance sheet.
- Total SABS debt is lower than 5 years ago, relative to shareholder equity.
Cons:
- SABS has $102.63M in cash and short term investments. This is not enough to cover its annual cash burn of $57.44M.
Is SABS stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 7 Equities analysts who track SABS, the consensus analyst rating on SABS is a Strong Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they financial advice.
Latest SABS Analyst Forecasts
Roger Song, a top 16% analyst from Jefferies initiates coverage on SABS with a strong buy rating and announces their SABS price target of $11.00, on May 20, 2026.
Seema Sheoran, a bottom 20% analyst from Rodman & Renshaw reiterates SABS with a strong buy rating and maintains their SABS price target from $13.00 to $13.00, on May 11, 2026.
You can dig deeper into what analysts are saying on the Sab Biotherapeutics stock forecast page.
SABS Technicals
How are SABS Revenues/Earnings doing?
Last year, SABS revenue was $0.00. In the last 5 year, SABS's revenue has increased by -100% per year. This was slower than the Biotechnology industry average of 24.78%.
Find out more about SABS's earnings and revenue performance here.
Are SABS insiders buying or selling the stock?
In the last year, executives and large shareholders at SABS have bought more shares than they have sold.
Andrew Moin, Director of SABS, was the latest SABS insider to buy. They bought $3,045,000.00 worth of SABS shares on Sep 29, 2025.
Get more info about who owns SABS stock here.
Can I rely on SABS as an income stream?
No, Sab Biotherapeutics doesn't provide an income stream by paying out dividends.
SABS Social Trading Data
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Make your SABS purchase
There are two primary options:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are usually sufficient. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at an exact price limit, use a limit order.
Click the Open Trade button and your broker will place your order.
If you want additional help buying stocks on eToro, watch the how to video below:
Step 6: Get updates on your SABS investment
Now that you own some shares in SABS, you'll want to keep up with your new investment.
Add SABS to a watchlist to keep tabs on your SABS stock.
SABS Feed
How to Buy Stock in Sab Biotherapeutics
To reiterate, here are the 6 steps you need to take to buy Sab Biotherapeutics stock right now:
- Decide where to buy Sab Biotherapeutics stock
- Create a brokerage account
- Fund your brokerage account
- Research Sab Biotherapeutics stock
- Make your SABS purchase
- Get updates on your SABS investment
If you require a brokerage account, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to get notifications regarding your new investment in Sab Biotherapeutics, click the button below.
Trending Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.